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Abstract
Primary renal chondrosarcomas are rare tumors that are high-grade in nature and, unfortunately, have poorly understood pathogenesis and 
extremely low prognosis. The coexistence of a discrete malignancy in the urinary bladder is even rarer, with the occurrence of distinct papillary 
urothelial carcinoma in the urinary bladder in this case. The clinical presentation is nonspecific, and the primary radiological investigations have 
a limited scope in providing specific diagnosis of this entity. The final diagnosis is possible on thorough histopathological examination of the 
resected specimen, which requires extensive sampling and meticulous reporting. As of now, the only way to achieve a better prognosis is by early 
diagnosis. It is necessary to keep the possibility of occurrence of sarcomas at rare sites in the differential diagnoses. The cytogenetic and molec-
ular abnormalities associated with this entity need to be elucidated to achieve a more satisfactory outcome concerning the overall management 
of the patient.
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Primary renal sarcomas are uncommon tumors, accounting 
for only 1%– 5% of all renal malignancies (1). Of these, pri-
mary renal chondrosarcomas are extremely rare, with only a 
few cases reported in the literature.
This high-grade malignancy has unique biphasic histol-
ogy with poorly understood pathogenesis, disease course, 
and even poorer prognosis (2). Herein we describe the first 
case report documenting the occurrence of primary renal 
chondrosarcoma in L-shaped crossed fused renal ectopia 
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that involves both moieties, along with a distinct papillary 
urothelial carcinoma in the urinary bladder.
Case Report
A 50-year-old male presented with hematuria, increased fre-
quency, and burning sensation during micturition along with 
left flank pain for 2 months. There was a history of general-
ized weakness, weight loss, and loss of appetite during this 
period. On examination, the patient was poorly nourished 
with the presence of a palpable left-sided abdominal mass.
Ultrasonography (USG) of the abdomen showed the pres-
ence of right ectopic kidney and left-sided hydronephrosis. 
A heterogeneous mass was noted in the left kidney. Another 
polypoidal mass was also seen in the lumen of the urinary 
bladder, attached to its posterolateral wall. 
Contrast-enhanced computerized tomography (CECT) 
of the abdomen helped in the renal anatomy and character-
ization of the mass, which revealed L-shaped crossed fused 
renal ectopia. The right kidney was not present in the right 
renal fossa and was in the midline, anterior to the aortic 
bifurcation at the L4-L5 level. It was malrotated and fused 
with the lower pole of the left kidney. The left kidney was 
enlarged, with a large soft heterogeneous tissue density mass 
involving the interpolar and lower pole regions that exhib-
ited heterogeneous enhancement with central non-enhancing 
areas. Few calcified foci were seen in the mass, along with 
moderate hydronephrosis. In the delayed phase (15 minutes), 
no contrast excretion from the left kidney was recorded. The 
interpolar region of the right kidney was contiguously infil-
trated by the left lower pole renal mass. Small tumor thrombi 
were present in the segmental right renal veins draining the 
interpolar region. Aortocaval, para-aortic and left renal hilar 
lymphadenopathy were also noted. 
Along with these findings, a well-defined polypoidal mass 
was seen in the left posterolateral wall of the urinary bladder, 
infiltrating the left vesicoureteral junction. The middle and 
distal parts of the left ureter were contiguously involved by 
this urinary bladder mass. A peripheral rim of calcification 
was present. 
Because of the involvement of multifocal enhancing 
masses of the moieties of crossed fused renal ectopia, urinary 
bladder, and left ureter, the radiological differential diagno-
ses offered were multifocal transitional cell carcinoma, renal 
cell carcinoma (RCC)- mucinous adenocarcinoma variant 
with multifocal spread, and renal sarcoma. 
No distant lesion was found on metastatic work-up. 
Initially, transurethral resection of the bladder lesion 
was done. Microscopic examination showed features of 
noninvasive papillary urothelial carcinoma, predominantly 
low-grade with high-grade focal areas, along with exten-
sive dystrophic calcification and necrosis, and focal osseous 
metaplasia  (Figure 1).
The patient was then taken up for surgery for resection 
of the renal mass, and a left nephrectomy with partial right 
nephrectomy was also performed. The specimen was submit-
ted for histopathological examination. The results showed 
that the capsule was intact. Cut section of the left kidney 
showed a tumor measuring 14x11x10 cm, replacing the entire 
normal structure. The renal pelvis was not identified, and 
part of the right kidney consisted of cystic and solid areas, 
with tumor measuring 3x2.5x2 cm (Figure 2).
Multiple sections examined from both the kidneys showed 
a tumor composed of large areas of cartilaginous differen-
tiation along with tumor cells arranged in diffuse sheets 
and fascicles. Marked pleomorphism and mitotic activity 
were noted, 18-19/10hpf. There was an abrupt transition to 
well-differentiated nodules of hyaline cartilage. Interven-
ing stroma showed consistent focal areas of myxoid change 
with chronic inflammatory cell infiltrate. The focal osteoid 
formation was present, with numerous giant cells and apop-
totic debris. Areas of chicken-wire calcification and hemor-
rhage were also identified, along with large necrotic sections 
 (Figure 3).
The tumor cells were immunopositive for CD99 with 
strong S100 protein expression in the areas of cartilaginous 
differentiation, immunonegative for pan-cytokeratin, CK7, 
CK20, p63, desmin, and myogenin, and with retention of 
INI1 expression (Figures 4 and 5). These morphological and 
immunohistochemical features suggested the presence of pri-
mary chondrosarcoma in crossed fused renal ectopia involv-
ing both moieties.
The patient was lost to follow-up after discharge from the 
hospital after an uneventful postsurgical period of 2 weeks.
Discussion
Mesenchymal chondrosarcomas, first reported in 1959, are 
rare neoplasms and constitute about 1% of all chondrosar-
comas seen commonly in the skeleton, with one-third of the 
cases arising in soft tissues and other organs. The extraskel-
etal mesenchymal chondrosarcoma sites include the head 
and neck, lower extremities, trunk, and retroperitoneum 
(3,4). Primary renal chondrosarcoma is very rare, with only a 
handful of cases reported since the entity was first described 
in 1984 (5). 
Although rare, the occurrence of renal chondrosarcoma as 
a primary lesion is not unexpected, as the kidney and carti-
lage have the same mesodermal origin (4). However, the exact 
histogenesis is uncertain, and because of rarity of the entity, 
there have been very few studies regarding pathogenesis.
The most widely accepted hypothesis is that tumor devel-
opment occurs in two stages, with secondary malignant 
transformation in tissue scattered during embryogenesis. 
Recent theories suggest that this entity occurs because of 
the pathological mesenchymal differentiation in stem cells 
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Figure 1: Tumor in urinary bladder. Photomicrographs of tumour in urinary bladder, showing noninvasive papillary urothelial 
carcinoma (A, 4x), area of necrosis (B, 10x), focus of calcification (C, 10x), and tumour (D, 40x)
Figure 2: Gross image of the resected specimen. The photo-
graph shows cut sections of left and right kidney, with exten-
sive tumor.
(1). Few studies have evaluated the role of mesenchymal- 
epithelial transition in the pathogenesis (6). 
The tumor shows a characteristic growth, consisting of 
cellular undifferentiated tumor cell components and nests 
of well-differentiated cartilage. The transition from the 
undifferentiated component to the cartilage nests is usually 
abrupt. The differential diagnoses on light microscopy can 
include Ewing sarcoma, small cell osteosarcoma, dedifferen-
tiated chondrosarcoma, and hemangiopericytoma (3). The 
entity may be confused with Wilm’s tumor as the undifferen-
tiated tumor cells and cartilage can be mistaken as blastemal 
and mesenchymal components (7). However, the character-
istic appearance and the absence of osteoid formation and 
immunohistochemical studies help in the diagnosis.
Extensive sampling and thorough histological examina-
tion are necessary to rule out the existence of RCC showing 
extensive mesenchymal differentiation with composite mor-
phology. Sarcomatoid change inclusive of osteosarcomatous 
and chondrosarcomatous differentiation is not uncommon 
in RCCs and has been widely reported (8). In our case, even 
after examining multiple sections from various locations, 
there was no evidence of RCC.
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Figure 3: Tumor in kidney. Photomicrographs of tumour in kidney, showing tumour (A, 10x), areas of cartilaginous differentia-
tion (B and C, 10x and 40x), and high mitotic activity (D, 40x).
Figure 4: Immunohistochemical findings. Photomicrographs showing immunopositivity of tumor cells for CD99 (A) and S100 
protein (B), retention of INI1 expression (C), and immunonegativity for pan cytokeratin (D).
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Figure 5: Immunohistochemical findings. Photomicrographs showing immunonegativity of tumor cells for CK7 (A), p63 (B), 
myogenin (C), and HMB45 (D).
Crossed fused renal ectopia  is a rare congenital anomaly 
wherein the kidneys are fused and located on the same side 
of the midline. It is subclassified into various types based 
on the configuration of fusion abnormality. In this case, the 
presence of this anomaly and involvement of both moieties 
increased the surgical complexity. However, preoperative 
evaluation of the renal and vascular anatomy using imaging 
played a vital role in the overall management of the patient. 
To the best of our knowledge, the occurrence of coexis-
tent renal chondrosarcoma in crossed fused renal ectopia 
involving both moieties, with papillary urothelial carcinoma 
in the urinary bladder has not been reported earlier. A previ-
ous case report described these entities occurring as separate 
lesions in the same kidney (9). This association may be coin-
cidental or can be a response to a common causative factor. 
Imaging studies play an integral role in the evaluation of 
an abdominal mass. However, to date, no specific radiolog-
ical features aid in the diagnosis of renal chondrosarcoma. 
The most common radiological finding is the occurrence 
of calcification within the tumor (1). Also, the diagnosis of 
primary renal chondrosarcoma necessitates exclusion of 
metastasis to the kidney from a skeletal chondrosarcoma by 
imaging.
Most of the cases of primary renal chondrosarcoma 
reported in literature had metastasis at initial presentation. 
The sites for metastasis include the liver, lung, ureter, thyroid 
gland, and femora (2,10). Simultaneous occurrence of mes-
enchymal chondrosarcoma in the kidney and spleen has also 
been reported (11). 
There are very few studies regarding the cytogenetic and 
molecular abnormalities in renal chondrosarcomas. FLI-1 
expression seen in Ewing sarcoma differentiates it from mes-
enchymal chondrosarcoma and small cell osteosarcoma (12). 
HEY1-NCOA2 fusion is considered to be diagnostic for 
mesenchymal chondrosarcomas (13). In bones, chondrosar-
comas exhibit p53 mutations only in a minority of cases. 
When present, these occur in higher grade tumors (14).
Increased p53 expression is associated with an overall 
poorer prognosis in RCCs (15). However, there is a short-
age of studies regarding the same concerning primary renal 
chondrosarcomas. Also, the association with hereditary syn-
dromes has not been established, probably because of the 
rarity of the condition.
In the absence of a definite treatment protocol, radical sur-
gical resection with adequate margins and adjuvant chemo-
therapy with multiple agents are used for management (16).
A possible chemotherapy regimen for adjuvant therapy is 
the combination of doxorubicin, vincristine, and cyclophos-
phamide, along with administration of etoposide and ifos-
famide. The malignant mesenchymal cells show increased 
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expression of platelet-derived growth factor receptor α 
(PDGFR-α). So agents that inhibit PDGFR-α function, 
such as dasatinib, sorafenib, and imatinib, may play a role in 
the therapy (17). 
Conclusion
The disease course of primary renal chondrosarcoma is 
poorly understood because of its rarity and poor survival 
rates. Elucidation of cytogenetic and molecular abnormali-
ties will help in designing a definite treatment protocol. As of 
now, a better prognosis may be achieved by early diagnosis 
and prompt initiation of appropriate management. It is nec-
essary to keep in mind the possible occurrence of sarcomas 
at rare sites because in such unusual cases, the period avail-
able for altering the disease outcome is limited.
Consent
Written informed consent was obtained as per institutional 
guidelines.
Conflict of Interest 
The authors declare no potential conflict of interests.
References
1. Buse S, Behnisch W, Kulozik A, Autschbach F, Hohenfellner M. 
Primary Chondrosarcoma of the Kidney: Case Report and 
Review of the Literature. Urol Int. 2009;83:116–8. https://doi.
org/10.1159/000224880
2. Chen D, Ye ZI, Wu X, Shi B, Zhou L, Sun S, Wei B, et al. 
Primary mesenchymal chondrosarcoma with bilateral kidney 
invasion and calcification in renal pelvis : A case report and 
review of the literature. Oncol Lett. 2015;10:1075–8. https://doi.
org/10.3892/ol.2015.3252
3. Xu H, Shao M, Sun H, Li S. Primary mesenchymal chondrosar-
coma of the kidney with synchronous implant and infiltrating 
urothelial carcinoma of the ureter. Diagn Pathol. 2012;7:125–7. 
https://doi.org/10.1186/1746-1596-7-125
4. Takuji K, Suzuki Y, Takata RYO, Takata KOH, Sakuma  T, 
Fujioka T. Extraskeletal mesenchymal chondrosarcoma 
of the kidney. Int J Urol. 2006; 13:285–6. https://doi.
org/10.1111/j.1442-2042.2006.01293.x
5. Malhotra C, Doolittle C, Rodil J, Vezeridis M. Mesenchymal 
chondrosarcoma of the kidney. Cancer. 1984;54:2495–9. https://
doi.org/10.1002/1097-0142(19841201)54:11<2495::AID-CN-
CR2820541130>3.0.CO;2-G
6. Daniel R, Silvia G, De la Cueva T, Paz M, Lloyd A, Antonio B, 
et al. Human mesenchymal stem cell transformation is associ-
ated with a mesenchymal-epithelial transition. Exp Cell Res. 
2008;314:691–8. https://doi.org/10.1016/j.yexcr.2007.11.017
7. Tyagi R, Kakkar N, Vasishta RK, Aggarwal MM. Mesenchymal 
chondrosarcoma of kidney. Int J Urol. 2014;30:225–7. https://
doi.org/10.4103/0970-1591.126914
8. Husain A, Eigl B, Trpkov K. Composite chromophobe renal cell 
carcinoma with sarcomatoid differentiation containing osteo-
sarcoma, chondrosarcoma, squamous metaplasia and asso-
ciated collecting duct carcinoma: A case report. Anal Quant 
Cytopathol Histopathol. 2014;36:235–40. Available from: 
https://pubmed.ncbi.nlm.nih.gov/25291862/
9. Callagher J, Winslow D, Grossman A. Coexistent chondro-
sarcoma and transitional-cell carcinoma in kidney. Urology. 
1974;3:473–7. https://doi.org/10.1016/S0090-4295(74)80167-6
10. Mehanna D, Rao S. Liver metastasis in renal chondrosar-
coma. Singapore Med J. 2004;45:183–5. Available from: https://
pubmed.ncbi.nlm.nih.gov/15094989/
11. Pani KC, Yadav M, Priyaa PV, Kumari N. Extraskeletal mes-
enchymal chondrosarcoma at unusual location involving spleen 
and kidney with review of literature. Ind J Pathol Microbiol. 
2017;60:262–5. https://doi.org/10.4103/IJPM.IJPM_16_16
12. Lee A, Hayes M, Lebrun D, Espinosa I, Nielsen G, Rosenberg 
A, et al. FLI-1 distinguishes Ewing sarcoma from small cell 
osteosarcoma and mesenchymal chondrosarcoma. Appl 
Immunohistochem Mol Morphol. 2011;19:233–8. https://doi.
org/10.1097/PAI.0b013e3181fd6697
13. Wang L, Motoi T, Khanin R, Olshen A, Mertens F, Bridge J, et 
al. Identification of a novel, recurrent HEY1-NCOA2 fusion in 
mesenchymal chondrosarcoma based on a genome-wide screen 
of exon-level expression data. Genes Chromosomes Cancer. 
2012;51:127–39. https://doi.org/10.1002/gcc.20937
14. Terek RM, Healey JH, Garin-Chesa P, Mak S, Huvos A, 
Albino AP. p53 mutations in chondrosarcoma. Diagn Mol Pathol. 
1998;7:51–6. https://doi.org/10.1097/00019606-199802000-00009
15. Noon AP, Vlatkovic N, Polanski R, Maguire M, Shawki H, 
Parsons K, et al. p53 and MDM2 in renal cell carcinoma: 
Biomarkers for disease progression and future therapeutic 
targets? Cancer. 2010;116:780–90. https://doi.org/10.1002/
cncr.24841
16. Gherman V, Tomuleasa C, Bungardean C, Crisan N, Ona V, 
Feciche B, et al. Management of renal extraskeletal mesenchy-
mal chondrosarcoma. BMC Surg. 2014;14:107–10. https://doi.
org/10.1186/1471-2482-14-107
17. Salehipour M, Hosseinzadeh M, Sisakhti AM, Parvin VAM, 
Sadraei A, Adib A. Renal extra skeletal mesenchymal chondro-
sarcoma: A case report. Urol Case Rep. 2017;12:23–5. https://
doi.org/10.1016/j.eucr.2016.12.013
